RNTX (STOCKS)
Rein Therapeutics, Inc. Common Stock
$1.550000
+0.060000 (+4.03%)
Prev close: $1.490000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Brian J. Windsor
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $43.32M
- Employees
- 11
- P/E (TTM)
- -0.79
- P/B (TTM)
- -1.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.09 | $-0.22 | -0.8730 | -398.08% |
|
Sep 2025 (Q3)
|
$-0.21 | $-0.24 | +0.0348 | +14.22% |
|
Jun 2025 (Q2)
|
$-0.28 | $-0.22 | -0.0556 | -24.78% |
|
Mar 2025 (Q1)
|
$-0.25 | $-0.25 | -0.0001 | -0.04% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $50.63M |
| Research and Development | $11.03M |
| Other Operating Expenses | $39.60M |
| Operating Income/Loss | -$50.63M |
| Income/Loss From Continuing Operations After Tax | -$49.87M |
| Income/Loss From Continuing Operations Before Tax | -$50.58M |
| Income Tax Expense/Benefit | -$712.00K |
| Income Tax Expense/Benefit, Current | $0.00 |
| Income Tax Expense/Benefit, Deferred | -$712.00K |
| Net Income/Loss | -$49.87M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$49.87M |
| Net Income/Loss Available To Common Stockholders, Basic | -$49.87M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.96 |
| Diluted Earnings Per Share | -$1.96 |
| Basic Average Shares | 25,444,795 |
| Diluted Average Shares | 25,444,795 |
| Assets | $24.16M |
| Current Assets | $4.33M |
| Noncurrent Assets | $19.83M |
| Fixed Assets | $0.00 |
| Intangible Assets | $13.50M |
| Other Non-current Assets | $6.33M |
| Liabilities | $7.24M |
| Current Liabilities | $6.18M |
| Accounts Payable | $3.98M |
| Wages | $940.00K |
| Other Current Liabilities | $1.26M |
| Noncurrent Liabilities | $1.06M |
| Equity | $16.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $16.92M |
| Temporary Equity | $45.01M |
| Temporary Equity Attributable To Parent | $45.01M |
| Liabilities And Equity | $24.16M |
| Net Cash Flow From Operating Activities | -$19.36M |
| Net Cash Flow From Operating Activities, Continuing | -$19.36M |
| Net Cash Flow From Investing Activities | $9.65M |
| Net Cash Flow From Investing Activities, Continuing | $9.61M |
| Net Cash Flow From Financing Activities | $9.76M |
| Net Cash Flow From Financing Activities, Continuing | $9.76M |
| Exchange Gains/Losses | -$44.00K |
| Net Cash Flow | $44.00K |
| Net Cash Flow, Continuing | $88.00K |
| Comprehensive Income/Loss | -$49.92M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$49.92M |
| Other Comprehensive Income/Loss | -$44.00K |
| Other Comprehensive Income/Loss Attributable To Parent | -$44.00K |